Fleming CFO, Inc.’s Post

“Fifty biopharmas raised $100 million or more during this year's second quarter. J.P. Morgan specifically name-dropped Xaira Therapeutics’ whopping $1 billion in committed capital that was announced in April along with Formation Bio’s $372 million series D from June. AltruBio Inc. also raised $225 million through a series B in May. Early-stage funding was also healthy, according to J.P. Morgan. Seed and Series A fundraising totaled $5.1 billion across 105 rounds in the first half; most of these were announced in the second quarter with huge initial values. Xaira was among those, as was Diagonal Therapeutics with a $128 million raise. Fundraising primarily focused on companies with candidates in the clinic, which is a change from last year, according to J.P. Morgan. Phase 1 companies raised a median round of $76 million in the second quarter, which is double the figure from the same period a year earlier. For phase 3 companies, the median was $100 million, which is more than double the full-year 2023 value for late-stage companies. #Biologics and #smallmolecules continue to attract the most popular investments and licensing deals. Pharmas stuck to licensing partnerships, which continue to see a larger share of the deal value across the industry, for overall deal activity. These deals also saw a continued trend toward smaller upfront payments and steep milestones that may or may not be paid out later, J.P. Morgan noted.” Fierce Biotech #biotech #biopharma #pharma #lifesciences #researchanddevelopment #research #science #scienceandtechnology https://lnkd.in/gu9fuDNE

Thoughts on this? >> J.P. Morgan Raises Over $500M for First Biotech Venture Capital Fund - BioSpace >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #competitivemarketing #biotech #pharma #healthcare

New Venture Fund - J.P. Morgan's $500M Biotech Arm J.P. Morgan announced last week the closing of their $500M biotech funding arm that will be targeting private biotechnology companies in an agnostic fashion, with no particular focus on any therapy area, geography, modality or development stage. Great news following a similar announcement from Goldman Sachs at the start of this year (which has already translated into $90M of funding into MOMA Therapeutics, Nested Therapeutics, TORL Biotherapeutics, Septerna and Rapport Therapeutics.) Source below: https://lnkd.in/eQRmP7Uw #lifesciences #biotechnology #pharmaceuticals #funding #venturecapital

Thoughts on this? >> J.P. Morgan Raises Over $500M for First Biotech Venture Capital Fund - BioSpace >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharmaceutical #pharma #biotech #healthcare #competitivemarketing

Arch Venture Partners has closed a remarkable $3 billion fund, marking a pivotal moment for the biotech industry. This substantial investment signals a renewed confidence among investors, indicating that more capital is poised to flow into the sector. As we witness signs of recovery in the market, this funding not only supports existing biotech companies but also paves the way for groundbreaking innovations in pharma/biotech. It's a testament to the resilience of our industry and the commitment to driving forward essential therapies. Let’s embrace this positive momentum! #Biotech #Investment #MarketRecovery #Innovation #Pharmaceuticals #LifeSciences #Healthcare #Executivesearch #TylerLakeConsulting

Thoughts on this? >> Regeneron Launches $500M Venture Capital Fund Skewed Toward Biotech - BioSpace >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #competitivemarketing #healthcare #pharmaceutical

https://lnkd.in/ee3-f7yw JP Morgan has released its Biopharma and Medtech Licensing and Venture Reports for Q2, and there are some interesting findings in the report. Venture investment in biopharma and medtech companies has been continuing its upward trend through the first half of 2024. The total amount of capital invested in biopharma therapeutics and discovery platforms grew in the second quarter of 2024 and notched the highest quarterly investment total since the first quarter of 2022. Medtech is also trending in a positive direction with 2024 on track to outpace the total amount of capital invested last year. In addition, M&A activity has been gaining traction through the first half of the year as well; the total amount of medtech M&A deals through Q2 has nearly matched 2023’s full-year total.  #lifescience #biotech #medtech #medicaldevice #healthtech #

Check out Monroe Hatch's most recent blog post!

Exciting news in biotech - Q1 2024 saw a 46% surge in venture funding, signaling a strong recovery. Late-stage clinical developments and innovative therapies like ADCs and radiopharmaceuticals received significant investments. The important question is what does this mean for the future of biotech? How will these trends impact the development of new therapies? And how is investor confidence changing as the IPO market sort of re-opens? Interesting thoughts to consider. You can read more on our blog: https://ow.ly/bpCF50S2iY6 #Biotech #VentureCapital #HealthcareInvestments

Is the Inflation Reduction Act impacting pharmaceutical industry decision making? You may be aware the IRA gives biologics a longer timeline than small molecules before price negotiations start. This could certainly impact investment in developing small molecules. I’ve done some data analysis using IPM Integrated Project Management Company's database of Venture Capital investment in start-up Pharma/Biotech companies to see what the VC’s are doing. The results might surprise you. #FromStrategyToExecution